An Investigation into the Prevalence of Migraine and Its Prophylactic Treatment Patterns in the Czech Republic: An Observational Study

por Dolezil, David, Markova, Jolana, Klimes, Jiri, Pocikova, Zuzana, Dostal, Filip, Stepanova, Radka, Svobodnik, Adam
Publicado 2020

A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine preven...

por Ashina, Messoud, Doležil, David, Bonner, Jo H, Zhou, Lifen, Klatt, Jan, Picard, Hernan, Mikol, Daniel D
Publicado 2020

Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial

por Reuter, Uwe, Lucas, Christian, Dolezil, David, Hand, Austin L., Port, Martha D., Nichols, Russell M., Stroud, Chad, Tockhorn-Heidenreich, Antje, Detke, Holland C.
Publicado 2021

Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis

por Ashina, Messoud, Tepper, Stewart J., Brandes, Jan Lewis, Reuter, Uwe, Boudreau, Guy P., Weatherall, Mark, Gantenbein, Andreas R., Doležil, David, Klatt, Jan, Wang, Andrea, Karanam, Ananda Krishna, Cheng, Sunfa, Mikol, Daniel D.
Publicado 2022